aRBD-2-7
A biparatopic anti-RBD (SARS-CoV-2 Spike) antibody.
General information
aRBD-2-7 is a hetero-bivalent (biparatopic) nanobody construct prepared by fusion of two anti-RBD (SARS-CoV-2) nanobodies identified in immunized alpacas. The parent nanobodies were identified using a phage display technique. The hetero-bivalent nanobody showd sub-nanomolar KD and ND50in vitro (Ma et al., 2021).
Supporting references
Link | Tested on | Impact factor | Notes | Publication date |
---|---|---|---|---|
Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
Spike protein Biophysical assay In vitro Antibody |
alpacas (sera donors); in vitro binding assay; in vitro biophysical assay; Vero E6 cells; SARS-CoV-2 isolate USA-WA1/2020 | 4.50 | The nanobody construct binds RBD with a KD of 0.25 nM (0.22 nM for an Fc fusion construct) and neutralizes SARS-CoV-2 with an ND50 of ca. 0.111 nM in vitro. |
Mar/03/2021 |